Daiichi Sankyo taps Ken Keller to lead commercial restructuring
Daiichi Sankyo is reorganizing its commercial operations, with Ken Keller appointed as chief commercialization officer. The changes, effective April 1, 2027, will split the company's commercialization efforts. The move aims to streamline the Japanese pharma's market approach.
Related stories
Lonza adds commercial chief from Celonic; WuXi Biologics posts revenue gain · Drug development
Replimune Appoints New Commercial Chief; Neumora Shakes Up Executive Ranks · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO.” Browse more stories.